Literature DB >> 8097105

Adoptive tumour immunotherapy using human CD4+ T-cells.

J E Gold, M E Osband.   

Abstract

Entities:  

Mesh：

Year:  1993        PMID： 8097105      PMCID： PMC1968373          DOI： 10.1038/bjc.1993.159

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  3 in total

1.  Purified human T cells stimulated with cross-linked anti-CD3 monoclonal antibody OKT3: rIL-1 is a co-stimulatory factor for CD4+CD29+CD45RA- T cells.

Authors:  S Panzer; R L Geller; F H Bach
Journal:  Scand J Immunol       Date:  1990-10       Impact factor: 3.487

2.  Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma.

Authors:  M E Osband; P T Lavin; R K Babayan; S Graham; D L Lamm; B Parker; I Sawczuk; S Ross; R J Krane
Journal:  Lancet       Date:  1990-04-28       Impact factor: 79.321

3.  Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumour immunotherapy.

Authors:  Y Nakamura; Y Tokuda; M Iwasawa; H Tsukamoto; M Kidokoro; N Kobayashi; S Kato; T Mitomi; S Habu; T Nishimura
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.